| abstract |
The present invention is mediated by conjugates of anti-integrin specific antibodies and cytotoxic compounds, cancer therapy or cell proliferation, cell migration, or inflammation, and where such lesions are used in other diseases including angiogenesis or neovascularization of new tissue. It relates to the synthesis, selection and use of conjugates. The invention also relates to combination therapies for such diseases, including the use of conjugates, in combination with one or more other therapies, including but not limited to chemotherapy, surgery or radiation therapy. Preferred conjugates contain maytansinoid compounds bound to the antibody by disulfide bonds, and preferred chemotherapeutic agents are doxorubicin, taxanes, camptothecins, grapephytotoxins, nucleoside analogs, or pyrimidine analogs. |